


Reference is made to the announcement today from Vistin Pharma ASA ("Vistin
Pharma") regarding the final result of the Rights Offering and Employee
Offering.  The following primary insiders of Vistin Pharma have been allocated
shares in the Rights Offering and/or Employee Offering:

Kjell-Erik Nordby, CEO, has been allocated 200,000 new shares at a subscription
price of NOK 10.00 per share. After this transaction Kjell-Erik Nordby will
hold 200,000 shares in Vistin Pharma.

Gunnar Manum, CFO, has been allocated 104,887 new shares at a subscription price
of NOK 10.00 per share. After this transaction Gunnar Manum will hold 104,887
shares in Vistin Pharma.

Valborg Godal Vold, VP Sales & Marketing, has been allocated 100,000 new shares
at a subscription price of NOK 10.00 per share. After this transaction Valborg
Godal Vold will hold 100,000 shares in Vistin Pharma.

Liesl Hellstrand, VP HR & Organisation, has been allocated 100,000 new shares at
a subscription price of NOK 10.00 per share. After this transaction Liesl
Hellstrand will hold 100,000 shares in Vistin Pharma.

Hilde Merete Næss, VP QA, has been allocated 30,000 new shares at a subscription
price of NOK 10.00 per share. After this transaction Hilde Merete Næss will
hold 30,000 shares in Vistin Pharma.

Gitte Jensen Vegge, VP Operations, has been allocated 10,000 new shares at a
subscription price of NOK 10.00 per share. After this transaction Gitte Jensen
Vegge will hold 10,000 shares in Vistin Pharma.

Ole Enger, the Chairman of Vistin Pharma, has been allocated 141,471 new shares
at a subscription price of NOK 10.00 per share. After this transaction Ole Enger
will hold 141,471 shares in Vistin Pharma.

Kathrine Gamborg Andreassen, a board member of Vistin Pharma, has been allocated
50,000 new shares at a subscription price of NOK 10.00 per share. After this
transaction Kathrine Gamborg Andreassen will hold 50,000 shares in Vistin
Pharma.

Einar J. Greve, a board member of Vistin Pharma from 10 June, has, through
Cipriano AS, a company controlled by him, been allocated 375,538 new shares at a
subscription price of NOK 10.00 per share. After this transaction Einar J. Greve
will indirectly hold 375,538 shares in Vistin Pharma.


[HUG#1926675] 
    